Publications

Found 82 Results
Page 1 of 9

Deep Cyclic Inhibition of the MAPK pathway with IMM-6-415, alone and in combination with encorafenib, demonstrates anti-tumor activity and tolerability in RAF mutant tumors in vivo

Anti–tumor activity of IMM-6-415 was evaluated in more than 60 humanized 3D-TGA models, which included 30 BRAF class I-mutant tumor models. Multiple drug-drug combinations have been explored, including vertical drug…


Predicting activity of IMM-1-104 as single agent and in combination for patients with RAS or RAF mutant tumors

Anti-tumor activity of IMM-1-104 was characterized in 193 tumor models spanning 20 distinct tumor types in the humanized 3D-tumor growth assay (3D-TGA) using cancer-specific, patient-aligned cell lines.  IMM-1-104 demonstrated diverse…


Humanized 3D tumor models that are mutually aligned with AACR GENIE patients predict IMM-1-104 activity in RAS-addicted tumors

Highlights of the initial IMM-1-104 Phase 1 PK, PD and safety data presented at AACR include (as of data cut-off date of April 10, 2023, including patients with pancreatic and…


Pan-RAS IMM-1-104 activity in humanized 3D tumor models is independent of specific amino acid substitution

Title: Pan-RAS IMM-1-104 activity in humanized 3D tumor models is independent of specific amino acid substitution Virtual poster presented at AACR Special Conference Targeting RAS March 7, 2023 Presenter: Sarah…


Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity

Broad response demonstrated through deep cyclic inhibition of MAPK pathway, independent of specific RAS mutation Phase 1/2a clinical trial with IMM-1-104 underway in patients with advanced solid tumors harboring RAS…


Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the Dual MEK inhibitor, IMM-6-415, enhances PD-1 and CTLA-4 checkpoint blockade in RAS mutant tumors

KRAS is the most frequently altered RAS gene (~85%) and is often mutated in pancreatic ductal adenocarcinoma (PDAC; 95%), non-small cell lung cancer (NSCLC; 40%) and colorectal cancer (CRC; 45%)1….


Translational Modeling for Patients with RAS Mutant Tumors: Profiling the Dual-MEK Inhibitor IMM-1-104 in a Humanized 3D Assay

Background: Elevated RAS-RAF-MEK-ERK (MAPK pathway) signaling is observed in over half of all solid human tumors, and mutations in RAS or RAF account for a large fraction. Given MEK’s unique…


Head-to-Head Comparison of the Dual-MEK Inhibitor IMM-1-104 versus Sotorasib or Adagrasib in KRAS Mutant Pancreatic Tumors

Background: KRAS mutations are common in pancreatic ductal adenocarcinoma (PDAC). While 90% of PDAC tumors display activating mutations in KRAS, only ~2% are G12C, a specific KRAS mutation targeted by…


Head-to-head comparison of the dual-MEK inhibitor IMM-1-104 versus binimetinib in NRAS mutant melanoma models

Title: Head-to-head comparison of the dual-MEK inhibitor IMM-1-104 versus binimetinib in NRAS mutant melanoma models Date: January 6, 2022 Presenter: Peter King, Ph.D., Immuneering Vice President, Head of Discovery Virtual…


Assessing reproducibility of inherited variants detected with short-read whole genome sequencing

Background Reproducible detection of inherited variants with whole genome sequencing (WGS) is vital for the implementation of precision medicine and is a complicated process in which each step affects variant…

Journal: Genome Biology


Page 1 of 9